Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
出版年份 2013 全文链接
标题
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF DERMATOLOGY
Volume 53, Issue 3, Pages 376-384
出版商
Wiley
发表日期
2013-07-25
DOI
10.1111/ijd.12205
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
- (2012) Sapna P Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiation-Induced Increase in Cell Migration and Metastatic Potential of Cervical Cancer Cells Operates Via the K-Ras Pathway
- (2011) Wen-Hong Su et al. AMERICAN JOURNAL OF PATHOLOGY
- Reacções cutâneas adversas aos inibidores do receptor do factor de crescimento epidérmico: estudo de 14 doentes
- (2011) Felicidade Santiago et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Meta-analysis of dermatological toxicities associated with sorafenib
- (2011) L. Zhang et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
- (2011) J. P. Arnault et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib
- (2011) BETH MCLELLAN et al. Dermatologic Therapy
- Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds
- (2011) Ithaisa Sologuren et al. HUMAN MOLECULAR GENETICS
- Sorafenib-induced premalignant and malignant skin lesions
- (2011) Victoria L. Williams et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
- (2011) Yevgeniy Balagula et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- (2011) Eve Maubec et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?
- (2011) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
- (2011) Yevgeniy Balagula et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244
- (2011) Christiane Querfeld et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours
- (2010) Ingrid M. E. Desar et al. ACTA ONCOLOGICA
- Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib
- (2010) T.K. Bulj et al. BRITISH JOURNAL OF DERMATOLOGY
- Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
- (2010) B. Nardone et al. CLINICAL CANCER RESEARCH
- Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- (2010) Yevgeniy Balagula et al. INVESTIGATIONAL NEW DRUGS
- Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’
- (2009) Stefan Boeck et al. ANTI-CANCER DRUGS
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
- (2009) W.J. Lee et al. BRITISH JOURNAL OF DERMATOLOGY
- Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
- (2009) Zita Dubauskas et al. Clinical Genitourinary Cancer
- The histologic spectrum of epithelial neoplasms induced by sorafenib
- (2009) Eun Ji Kwon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
- (2009) Adam D. Lipworth et al. ONCOLOGY
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- (2009) Tianhong Li et al. Targeted Oncology
- Skin reactions to the new biologic anticancer drugs
- (2009) Patricia L Myskowski et al. Current Opinion in Supportive and Palliative Care
- Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib
- (2008) David S. Hong et al. ARCHIVES OF DERMATOLOGY
- Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor
- (2008) Julien Autier et al. ARCHIVES OF DERMATOLOGY
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started